MBFT is developing products for the treatment of multiple types of solid tumor and blood cancers. Our lead products are:
MBFT-101, a combination therapy for sarcomas and lymphoma. MBFT-101 combines MBF-1569, a proprietary polyamine transport inhibitor, and DFMO (difluoromethylornithine), a potent inhibitor of Ornithine DeCarboxylase (ODC) the key enzyme that regulates cellular polyamine metabolism and that becomes dysregulated in forms of cancer. A clinical study with MBFT-101 in cats with nonresectable oral squamous cell carcinoma is underway at the University of Pennsylvania’s School of Veterinary Medicine. The study is partially supported by a Ben Franklin Technology Partners Technology Concept Network grant to MBF Therapeutics and Dr. Thomas O’Brien, a leading expert on the role of polyamines in cancer, at the Lankenau Institute for Medical Research (Wynnewood, PA).
MBFT 102, a potent immunotherapy product based on the tumor suppressor/cytokine mda-7/IL24, a DNA-based therapy that has demonstrated safety and efficacy in human patients with a variety of advanced cancers including melanoma, breast, colon, head and neck, lymphoma, hepatoma and adrenal carcinoma. MBFT is working with Dr. Paul Fisher, the inventor and leading expert on mda7/IL24, to adapt this therapy for use in dogs.
